News Stories

JACKSONVILLE, Fla. -- The National Lipid Association announced Monday it has united with MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, through Michael J. Hennessy Associates' Strategic Alliance Partnership (SAP) Program. The partnership will also include sister publications, Rare Disease Report® and Pharmacy Times®.

The National Lipid Association announced on Wednesday its support of the Lipoprotein(a) Foundation’s efforts to promote a new ICD-10 Diagnostic-Code for high Lp(a).

The NLA believes the new code will be beneficial in identifying lethal risk factors in patients. To further support this initiative, NLA members are encouraged to email the ICD-10 Coordination and Maintenance Committee before November 13, 2017. 

The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events.  Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels.  These favorable lipid changes were associated with a significant reduction in cardiovascular events